The combined organ effect: protection against rejection?

Area of Science:

• Transplantation immunology
• Organ allograft research
• Immunoprotection in combined transplants

Background:

• Liver allografts are traditionally considered immunoprotective for co-transplanted donor-specific allografts.
• Emerging evidence suggests this protective property extends to other organ types.

Purpose of the Study:

• To compare rejection-free survival and 1-year rejection rates in various combined organ transplants.
• To elucidate the immunoprotective effects of one allograft on another in simultaneous transplantation.

Main Methods:

• Analysis of a large cohort (n=133,416) from the United Network of Organ Sharing database.
• Inclusion criteria: recipients aged 18+, primary transplants (excluding intestinal), between 1994-2005.
• Exclusion criteria: previous transplants, live donors, insufficient follow-up.

Main Results:

• Co-transplanted liver, kidney, and heart allografts showed significantly lower rejection rates compared to single transplants.
• Intestinal or pancreatic allografts did not confer similar protective effects.
• Reduced rejection observed in interval kidney-heart transplants with partial antigenic identity and in double-organ transplants of the same type.

Conclusions:

• Simultaneous heart, liver, and kidney allografts are protected from rejection and offer protection to co-transplanted organs.
• Immunoprotection in interval heart-kidney transplants necessitates partial antigenic identity.
• Increased antigen load from identical antigens, as in double-lung or double-kidney transplants, also provides immunologic protection.